In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents

International Journal of Antimicrobial Agents

Volumn 50, Issue 2, 2017, Pages 191-196

  López Díaz, María Carmen ^a   Ríos, Esther ^a   Rodríguez Avial, Iciar ^a   Simaluiza, Rosa Janneth ^b   Picazo, Juan José ^a   Culebras, Esther ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSIDAD TÉCNICA PARTICULAR DE LOJA   (Ecuador)

Author keywords

Aminoglycoside modifying enzymes; Methicillin resistant Staphylococcus aureus; Plazomicin

Indexed keywords

DALBAVANCIN; MEROPENEM; PLAZOMICIN; 6'-(HYDROXYLETHYL)-1-(HABA)-SISOMICIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; SISOMICIN;

AAC GENE; ANT GENE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; APH GENE; ARTICLE; ASSAY; BACTERIAL GENE; BACTERIUM ISOLATE; CHECKERBOARD ASSAY; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIC50; MIC90; NONHUMAN; PRIORITY JOURNAL; TIME KILL ASSAY; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG INACTIVATION; ENZYMOLOGY; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY;

AMINOGLYCOSIDES; ANTI-INFECTIVE AGENTS; DRUG SYNERGISM; HUMANS; INACTIVATION, METABOLIC; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; SISOMICIN;

EID: 85020648222     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.01.039     Document Type: Article

References (28)

1. Köck, R., Becker, K., Cookson, B., van Gemert-Pijnen, J., Harbarth, S., Kluytmans, J., et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill, 15, 2010, 19688.
2. Howden, B.P., Davies, J.K., Johnson, P.D.R., Stinear, T.P., Grayson, M.L., Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23 (2010), 99–139.
3. Shaw, K., Rather, P., Hare, R., Miller, G., Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 57 (1993), 138–163.
4. McCurdy, S.P., Jones, R.N., Mendes, R.E., Puttagunta, S., Dunne, M.W., In vitro activity of dalbavancin against drug-resistant Staphylococcus aureus isolates from a global surveillance program. Antimicrob Agents Chemother 59 (2015), 5007–5009.
5. Sahuquillo Arce, J.M., Colombo Gainza, E., Gil Brusola, A., Ortiz Estévez, R., Cantón, E., Gobernado, M., In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter 19 (2006), 252–257.
6. Berditsch, M., Jäger, T., Strempel, N., Schwartz, T., Overhage, J., Ulrich, A.S., Synergistic effect of membrane-active peptides polymyxin B and gramicidin S on multidrug-resistant strains and biofilms of Pseudomonas aeruginosa. Antimicrob Agents Chemother 59 (2015), 5288–5296.
7. Micek, S.T., Welch, E.C., Khan, J., Pervez, M., Doherty, J.A., Reichley, R.M., et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 54 (2010), 1742–1748.
8. Ramirez, M.S., Tolmasky, M.E., Aminoglycoside modifying enzymes. Drug Resist Updat 13 (2010), 151–171.
9. Shokravi, Z., Mehrad, L., Ramazani, A., Detecting the frequency of aminoglycoside modifying enzyme encoding genes among clinical isolates of methicillin-resistant Staphylococcus aureus. Bioimpacts 5 (2015), 87–91.
10. Zhanel, G.G., Lawson, C.D., Zelenitsky, S., Findlay, B., Schweizer, F., Adam, H., et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 10 (2012), 459–473.
11. Tenover, F.C., Tickler, I., Armstrong, E.S., Kubo, A., Lopez, S., Persing, D.H., et al. Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals. Int J Antimicrob Agents 38 (2011), 352–354.
12. García-Salguero, C., Rodríguez-Avial, I., Picazo, J.J., Culebras, E., Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii?. Antimicrob Agents Chemother 59 (2015), 5959–5966.
13. Lin, G., Ednie, L.M., Appelbaum, P.C., Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay. Antimicrob Agents Chemother 54 (2010), 2258–2261.
14. Rodríguez-Avial, I., Pena, I., Picazo, J.J., Rodríguez-Avial, C., Culebras, E., In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents 46 (2015), 616–621.
15. Clinical Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; Twenty-Fourth informational supplement M100-S24. 2014, CLSI, Wayne, PA.
16. Martins, A., Pereira, V., Cunha, M.L., Oxacillin resistance of Staphylococcus aureus isolated from the university hospital of Botucatu Medical School in Brazil. Chemotherapy 56 (2010), 112–119.
17. European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0. EUCAST, 2015.
18. Livermore, D.M., Winstanley, T.G., Shannon, K.P., Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 48 (2001), 87–102.
19. Torres, C., Cercenado, E., Lectura interpretada del antibiograma de cocos gram positivos. Enferm Infecc Microbiol Clin 28 (2010), 541–553.
20. Choi, S.M., Kim, S.-H., Kim, H.-J., Lee, D.-G., Choi, J.-H., Yoo, J.-H., et al. Multiplex PCR for the detection of genes encoding aminoglycoside modifying enzymes and methicillin resistance among Staphylococcus species. J Korean Med Sci 18 (2003), 631–636.
21. Clark, N.C., Olsvik, Ø., Swenson, J.M., Spiegel, C.A., Tenover, F.C., Detection of a streptomycin/spectinomycin adenylyltransferase gene (aadA) in Enterococcus faecalis. Antimicrob Agents Chemother 43 (1999), 157–160.
22. Petersen, P.J., Labthavikul, P., Jones, C.H., Bradford, P.A., In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 57 (2006), 573–576.
23. Czaja, C.A., Levin, A., Moridani, M., Krank, J.L., Curran-Everett, D., Andersonf, P.L., Cefoxitin continuous infusion for lung infection caused by the Mycobacterium abscessus group. Antimicrob Agents Chemother 58 (2014), 3570–3571.
24. Tängdén, T., Hickman, R.A., Forsberg, P., Lagerbäck, P., Giske, C.G., Cars, O., Evaluation of double- and triple-antibiotic combinations for VIM and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 58 (2014), 1757–1762.
25. Gudiol, F., Aguado, J.M., Pascual, A., Pujol, M., Almirante, B., Miro, J.M., et al. Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Enferm Infecc Microbiol Clin 27 (2009), 105–115.
26. Walkty, A., Adam, H., Baxter, M., Denisuik, A., Lagacé-Wiens, P., Karlowsky, J., et al. In vitro activity of plazomicin against 5.015 Gram-negative and Gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob Agents Chemother 58 (2014), 2554–2563.
27. Ardic, N., Sareyyupoglu, B., Ozyurt, M., Haznedaroglu, T., Ilga, U., Investigation of aminoglycoside modifying enzyme genes in methicillin-resistant staphylococci. Microbiol Res 161 (2006), 49–54.
28. Klingenberg, C., Sundsfjord, A., Rønnestad, A., Mikalsen, J., Gaustad, P., Flægstad, T., Phenotypic and genotypic aminoglycoside resistance in blood culture isolates of coagulase-negative Staphylococci from a single neonatal intensive care unit, 1989–2000. J Antimicrob Chemother 54 (2004), 889–896.